Tsunehisa Nomura
Kurashiki, 7010192, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Peripheral Blood T-Cell Receptor Repertoire and Host Immune Background in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
Journal: Acta medica Okayama
Published: June 30, 2026
Association of zinc transporter expression with clinicopathological features and prognosis in patients with breast cancer.
Journal: Medical molecular morphology
Published: June 18, 2026
Validation of the Symptom Illustration Scale within an electronic Patient-Reported Outcomes Monitoring environment for metastatic breast cancer patients undergoing chemotherapy.
Journal: Breast cancer (Tokyo, Japan)
Published: December 17, 2024
The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition.
Journal: Breast cancer (Tokyo, Japan)
Published: September 29, 2023
Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
Journal: Breast cancer (Tokyo, Japan)
Published: May 20, 2023
Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.
Journal: Breast cancer (Tokyo, Japan)
Published: March 02, 2023
An extremely rare case of nonfunctioning parathyroid carcinoma occurring in a parathyroid adenoma.
Journal: Medical molecular morphology
Published: January 07, 2023
Neoadjuvant Epirubicin-Cyclophosphamide Therapy followed by Nab-Paclitaxel in Patients with Operable Breast Cancer-A Single-Center Phase Ⅱ Trial
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: July 08, 2022
A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
Journal: Anticancer research
Published: September 15, 2021
A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Journal: Anticancer research
Published: March 25, 2020
Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Journal: Anticancer research
Published: March 06, 2020
Last Updated: 09/26/2026